What is Chardan Capital’s Estimate for STOK FY2025 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Stoke Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst R. Li forecasts that the company will post earnings of ($1.75) per share for the year. Chardan Capital has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

A number of other analysts have also commented on STOK. HC Wainwright reissued a “buy” rating and set a $47.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, March 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Stoke Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $24.67.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $7.45 on Thursday. Stoke Therapeutics has a one year low of $7.18 and a one year high of $17.58. The business has a 50-day simple moving average of $9.36 and a 200 day simple moving average of $11.24. The firm has a market capitalization of $402.88 million, a price-to-earnings ratio of -3.55 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. The company had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Insider Activity

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares in the company, valued at $554,550.54. This trade represents a 5.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock valued at $143,332 over the last quarter. Company insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of large investors have recently modified their holdings of STOK. KLP Kapitalforvaltning AS purchased a new stake in Stoke Therapeutics in the 4th quarter worth approximately $63,000. Teacher Retirement System of Texas bought a new position in shares of Stoke Therapeutics in the fourth quarter worth $113,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Stoke Therapeutics in the fourth quarter worth $124,000. Tower Research Capital LLC TRC boosted its stake in Stoke Therapeutics by 70.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock valued at $132,000 after buying an additional 4,918 shares during the period. Finally, Invesco Ltd. purchased a new position in Stoke Therapeutics during the fourth quarter worth about $133,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.